2023年以来，国产ADC异军突起，并在国际舞台大放异彩。A/H市场先后诞生了百利天恒、科伦博泰生物（06990.HK）这样千亿市值级别的公司。ADC因其靶向特性而被称为“魔法子弹”。与化疗及上一代靶向疗法相比，同时具备特异性及强效抗癌特性的ADC已显示出其能够为患者提供更有效及更安全的治疗选择。这也让跨国药企（MNC）纷纷来国内扫货，并由此引爆了国创新药企的BD叙事。01自带阿尔法在2023年、...
Source Link2023年以来，国产ADC异军突起，并在国际舞台大放异彩。A/H市场先后诞生了百利天恒、科伦博泰生物（06990.HK）这样千亿市值级别的公司。ADC因其靶向特性而被称为“魔法子弹”。与化疗及上一代靶向疗法相比，同时具备特异性及强效抗癌特性的ADC已显示出其能够为患者提供更有效及更安全的治疗选择。这也让跨国药企（MNC）纷纷来国内扫货，并由此引爆了国创新药企的BD叙事。01自带阿尔法在2023年、...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.